Schonfeld Strategic Advisors LLC purchased a new stake in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 270,541 shares of the biopharmaceutical company's stock, valued at approximately $1,296,000. Schonfeld Strategic Advisors LLC owned about 0.46% of Vanda Pharmaceuticals as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in the company. XTX Topco Ltd bought a new position in Vanda Pharmaceuticals in the fourth quarter worth approximately $69,000. Zacks Investment Management bought a new stake in shares of Vanda Pharmaceuticals during the 4th quarter valued at $74,000. Price T Rowe Associates Inc. MD raised its position in shares of Vanda Pharmaceuticals by 17.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 22,265 shares of the biopharmaceutical company's stock valued at $107,000 after purchasing an additional 3,370 shares during the period. Tudor Investment Corp ET AL grew its stake in Vanda Pharmaceuticals by 59.5% during the fourth quarter. Tudor Investment Corp ET AL now owns 24,618 shares of the biopharmaceutical company's stock valued at $118,000 after acquiring an additional 9,180 shares in the last quarter. Finally, SG Americas Securities LLC grew its stake in Vanda Pharmaceuticals by 26.8% during the fourth quarter. SG Americas Securities LLC now owns 25,861 shares of the biopharmaceutical company's stock valued at $124,000 after acquiring an additional 5,459 shares in the last quarter. Hedge funds and other institutional investors own 88.14% of the company's stock.
Wall Street Analysts Forecast Growth
Several research firms recently weighed in on VNDA. StockNews.com began coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, February 5th. They set a "hold" rating for the company. HC Wainwright reaffirmed a "buy" rating and set a $20.00 target price on shares of Vanda Pharmaceuticals in a research note on Wednesday, May 7th.
Check Out Our Latest Stock Report on Vanda Pharmaceuticals
Vanda Pharmaceuticals Trading Down 1.5%
VNDA traded down $0.06 during trading on Tuesday, hitting $3.97. 220,458 shares of the company traded hands, compared to its average volume of 725,048. The company has a market cap of $233.97 million, a PE ratio of -12.41 and a beta of 0.69. The stock's 50-day simple moving average is $4.50 and its two-hundred day simple moving average is $4.65. Vanda Pharmaceuticals Inc. has a 1 year low of $3.85 and a 1 year high of $6.75.
Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.05. Vanda Pharmaceuticals had a negative net margin of 9.51% and a negative return on equity of 3.49%. The business had revenue of $50.04 million during the quarter, compared to analysts' expectations of $45.13 million. Equities analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 EPS for the current year.
Insiders Place Their Bets
In other news, CEO Mihael Hristos Polymeropoulos bought 10,000 shares of the stock in a transaction dated Friday, February 28th. The stock was purchased at an average price of $4.76 per share, for a total transaction of $47,600.00. Following the acquisition, the chief executive officer now owns 2,361,730 shares of the company's stock, valued at $11,241,834.80. The trade was a 0.43% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders acquired 32,000 shares of company stock valued at $151,180 in the last three months. Corporate insiders own 10.00% of the company's stock.
Vanda Pharmaceuticals Company Profile
(
Free Report)
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.
Featured Articles
Before you consider Vanda Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vanda Pharmaceuticals wasn't on the list.
While Vanda Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
